CAR-T cell therapy for recurrent brain glioma
Treatments studied
Part of Cancer clinical trials.
This trial tests a new type of immune cell therapy (CAR-T cells) made from donor cells, designed to target tumors with a specific marker called CD70. It is for people whose brain glioma has come back or hasn't responded to standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- Your brain tumor has come back or hasn't responded to standard therapy, and tests show it has a protein called CD70 at a certain level (2+ or higher).
- You have at least one tumor that can be measured on an MRI or other scan.
- You are expected to live at least 12 more weeks and are in fairly good health (able to do most daily activities).
- Your blood counts, liver, and kidney function are within certain safe ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial studies a personalized immune-cell treatment (CAR-T) for glioblastoma that has come back. It aims to shrink or control the regrowing brain tumor by using your own immune cells after processing them in a lab.
This trial tests a new CAR-T cell treatment (SNC-109) for people with glioblastoma that has come back after initial treatment. The therapy uses your own immune cells, modified in a lab, to try to attack the tumor.
This trial tests a new type of immunotherapy called CAR-T cells, made from donor cells, for people whose glioblastoma (a type of brain cancer) has come back after standard treatment. The goal is to see if it can shrink the tumor or slow its growth.
This trial tests a new type of immune cell therapy (CAR-T cells) that targets a protein called CD276 found on glioblastoma cells. It's for people whose glioblastoma has come back or not responded to standard treatments, and who have no other good options left.
This trial tests a new treatment called TX103 CAR-T cells for people with a grade 4 glioma (like glioblastoma) that has come back or gotten worse after standard treatment. The therapy uses your own immune cells that are specially trained to attack a marker called B7-H3 found on tumor cells.
This trial tests a new type of immunotherapy called CAR T-cells that target a protein called GARP on your tumor cells. It is for people whose high-grade glioma (a fast-growing brain tumor) has come back after previous treatment.
Hear when a new Gliomas trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.